mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2019-10-4-28-35mvjr-970Research ArticleОБЗОРЫREVIEWГлиобластомы: современное состояние проблемы.Glioblastoma: the current state of the problemЯковленкоЮ. Г.YakovlenkoY. G.

к.м.н., врач-нейрохирург отделения нейрохирургического Клиники, ассистент кафедры нервных болезней и нейрохирургии;

врач-нейрохирург, 

Ростов-на-Дону

Cand. Sci. (Med.), Neurosurgeon in Department of Neurosurgery, Clinic; Assistant of the Department of Neurology and Neurosurgery, Faculty of General Medicine;

neurosurgeon, 

Rostov-on-Don

Yuyakovlenko@gmail.comРостовский государственный медицинский университет; Областной консультативно-диагностический центрРоссияRostov State Medical University; Rostov Regional Advisory and Diagnostic CentreRussian Federation2019261220191042835Copyright © Яковленко Ю.Г., 20192019Яковленко Ю.Г.Yakovlenko Y.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/970

Представлен краткий литературный обзор современных научных данных о биологии наиболее злокачественных нейроэпителиальных опухолей — глиобластом центральной нервной системы. В статье обсуждаются вопросы эпидемиологии, классификации, молекулярно-генетической и рентгенологической диагностики, а также комплексного лечения данного вида опухолей у взрослых (> 20 лет) пациентов. Подробно освещены генетические и биохимические факторы развития глиобластом, описаны основные прогностические критерии эффективности химиотерапии. В заключительной части статьи представлен обзор основных трендов разработки экспериментальных методов лечения.

A brief literature review of modern scientifi c data on the biology of the most malignant neuroepithelial tumors — glioblastomas of the central nervous system is presented. Th e article discusses the issues of epidemiology, classifi cation, molecular genetic and radiological diagnostics, as well as the complex treatment of this type of tumor in adult (> 20 years old) patients. Genetic and biochemical factors of glioblastoma development are described in detail, the main prognostic criteria for the eff ectiveness of chemotherapy are presented. Th e article concludes with an overview of the main trends in the development of experimental treatment methods.

глиобластомаклассификациягенетикабиохимиялечениеglioblastomaclassificationgeneticsbiochemistrytreatmentReferencesЗолотова С.В., Хохлова Е.В., Беляшова А.С., Николаева А.А., Старовойтов Д.В. и др. Исследование метаболических особенностей первичных глиобластом методом ОФЭКТ-КТ с Tc-МИБИ с оценкой их влияния на прогноз заболевания. // Вопросы нейрохирургии им. Н.Н. Бурденко. - 2019. - Т. 83. 2. - С. 17-26. doi: 10.17116/neiro20198302117Zolotova SV, Khokhlova EV, Belyashova AS, Nikolaeva AA, Starovoytov DV, et al. Investigation of the metabolic features of primary glioblastomas by Tc-MIBI SPECT/CT and evaluation of their effect on disease prognosis. Zh Vopr Neirokhir Im N N Burdenko . 2019;83(2):17-26. (In Russ.) doi: 10.17116/neiro20198302117Горяйнов С.А., Гольдберг М.Ф., Голанов А.В., Золотова С В., Шишкина Л.В. и др. Феномен длительной выживаемости пациентов с глиобластомами. Часть I: Роль клинико-демографических факторов и мутации IDH1 (R 132 H). // Вопросы нейрохирургии им. Н.Н. Бурденко. - 2017. - Т. 81. № 3. - С. 5-16. doi: 10.17116/neiro20178135-16Goryaynov SA, Gol’dberg MF, Golanov AV, Zolotova SV, Shishkina LV, et al. The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H). Zh Vopr Neirokhir Im N N Burdenko. 2017;81(3):5-16. (in Russ.) doi: 10.17116/neiro20178135-16Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. // JAMA. - 2013. – V.310(17). – P.1842-50. doi: 10.1001/jama.2013.280319.Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-50. doi: 10.1001/jama.2013.280319.Harbaugh R., Shaff rey C.I., Couldwell W.T., Berger M.S. eds. Neurosurgery knowledge update: a comprehensive review 1st Edition. - New York: Th ieme; 2015.Harbaugh R, Shaff rey CI, Couldwell WT, Berger MS eds. Neurosurgery knowledge update: a comprehensive review 1st Edition. New York: Thieme; 2015.Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosedin the United States in 2011-2015. // Neuro Oncol. - 2018. – V.20(suppl_4). – P.iv1-iv86. doi: 10.1093/neuonc/noy131Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosedin the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131Ostrom Q.T., Bauchet L., Davis F.G., Deltour I., Fisher J.L., et al. Th e epidemiology of glioma in adults: a “state of the science” review. // Neuro-Oncology. – 2014. – V.16(7). – P. 896– 913. doi: 10.1093/neuonc/nou087Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, et al. Th e epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7), 896–913. doi: 10.1093/neuonc/nou087Sundar S.J., Hsieh J.K., ManJila S. Lathia J.D., Sloan A. Th e role of cancer stem cells in glioblastoma. // Neurosurg Focus. – 2014. – V.37(6). – P.E6. doi: 10.3171/2014.9.FOCUS14494Sundar SJ, Hsieh JK, ManJila S, Lathia JD, Sloan A. Th e role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6. doi: 10.3171/2014.9.FOCUS14494Кобяков Г.Л., Абсалямова О.В., Поддубский А.А., Лодыгина К.С., Кобякова Е.А. Классификация ВОЗ первичных опухолей центральной нервной системы 2016 г.: взгляд клинициста. // Вопросы нейрохирургии им. Н.Н. Бурденко. - 2018. - Т. 82. № 3. - С. 88-96. doi: 10.17116/neiro201882388Kobyakov GL, Absalyamova OV, Poddubskiy AA, Lodygina KS, Kobyakova EA. Th e 2016 WHO classifi cation of primary tumors of the central nervous system: a clinician’s opinion. Zh Vopr Neirokhir Im N N Burdenko. 2018;82(3):88-96. (In Russ.) doi: 10.17116/neiro201882388Banan R., Hartmann C. Th e new WHO 2016 classifi cation of brain tumors—what neurosurgeons need to know. // Acta Neurochir. – 2017. – V.159. – P.403-418. doi: 10.1007/s00701-016-3062-3Banan R, Hartmann C. Th e new WHO 2016 classification of brain tumors—what neurosurgeons need to know. Acta Neurochir 2017;159:403-418. doi: 10.1007/s00701-016-3062-3Agnihotri S., Aldape K.D., Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. // Neurosurg Focus. - 2014. – V.37(6). – P.E13. doi: 10.3171/2014.9.FOCUS14505.Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurg Focus. 2014;37(6):E13. doi: 10.3171/2014.9.FOCUS14505.Christensen B.C., Smith A.A., Zheng S., Koestler D.C., Houseman E.A., et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. // J Natl Cancer Inst. - 2011. – V.103(2). – P.143-53. doi: 10.1093/jnci/djq497Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011;103(2):143-53. doi: 10.1093/jnci/djq497/Margison G.P., Kleihues P. Chemical carcinogenesis in the nervous system. Preferential accumulation of O6-methylguanine in rat-brain deoxyribonucleic acid during repetitive administration of N-methyl- N-nitrosourea. // Biochem J. – 1975. – V.148. – P.521–525. doi: 10.1042%2Fbj1480521Margison GP, Kleihues P. Chemical carcinogenesis in the nervous system. Preferential accumulation of O6- methylguanine in rat-brain deoxyribonucleic acid during repetitive administration of N-methyl- N-nitrosourea. Biochem J. 1975;148:521–525. doi: 10.1042%2Fbj1480521Goth R., Rajewsky M.F. Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specifi c carcinogenesis by ethylnitrosourea. // Proc Natl Acad Sci U S A. – 1974. – V.71. – P.639–643.Goth R, Rajewsky MF. Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specifi c carcinogenesis by ethylnitrosourea. Proc Natl Acad Sci U S A. 1974;71:639–643.Greenberg M.S. Handbook of neurosurgery. Eighth Edition. - New York: Thieme; 2016.Greenberg MS. Handbook of neurosurgery. Eighth Edition. New York: Thieme; 2016.Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., et al. IDH1 and IDH2 mutations in gliomas. // N Engl J Med. – 2009. – V. 360(8). – P.765-773. doi: 10.1056/NEJMoa0808710.Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773. doi: 10.1056/NEJMoa0808710.Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. // Genes Dev. – 2007. – V.21. – P.2683– 2710. doi: 10.1101/gad.1596707Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–2710. doi: 10.1101/gad.1596707Ohgaki H., Kleihues P. Th e defi nition of primary and secondary glioblastoma. // Clin Cancer Res. – 2013. – V.19. – P.764– 772. doi: 10.1158/1078-0432.CCR-12-3002Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764–772. doi: 10.1158/1078-0432.CCR-12-3002Bello M.J., Alonso M.E., Aminoso C., Anselmo N.P., Arjona D., et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. // Mutat Res. – 2004. – V.554. – P.23–32. doi: 10.1016/j.mrfmmm.2004.02.011Bello MJ, Alonso ME, Aminoso C, Anselmo NP, Arjona D, et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res. 2004;554:23–32. doi: 10.1016/j.mrfmmm.2004.02.011Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter-methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C–>A:T mutations of theTP53tumor suppressor gene. // Carcinogenesis. – 2001. – V.22. – P.1715–1719. doi: 10.1093/carcin/22.10.1715Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter-methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C–>A:T mutations of theTP53tumor suppressor gene. Carcinogenesis. 2001;22:1715–1719. doi: 10.1093/carcin/22.10.1715Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., et al. An integrated genomic analysis of human glioblastoma multiforme. // Science. – 2008. – V.321. – P.1807–1812. doi: 10.1126/science.1164382Parsons DW, Jones S, Zhang X., Lin JC, Leary RJ, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. doi: 10.1126/science.1164382Румболт З., Кастильо М., Хуанг Б., Росси А. КТ- и МРТвизуализация головного мозга. - Москва, “Медпресс-информ”, 2016.Rumboldt Z, Castillo M, HuangB, Rossi A. Brain imaging with MRI and CT. An image pattern approach. Cambridge university press; 2012.Зартор К., Хэннэль С., Кресс Б. Лучевая диагностика: Головной мозг.; пер. с англ. – М.: МЕДпресс-информ, 2013.Sartor K., Haehnel S., Kress B. Direct diagnosis in radiology: Brain imaging. Stuttgart: Thieme; 2008.Shukla G., Alexander G.S., Bakas S., Nikam R., Talekar K., et al. Advanced magnetic resonance imaging in glioblastoma: a review. // Chin Clin Oncol. – 2017. – V.6(4). – P.40. doi: 10.21037/cco.2017.06.28Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6(4):40. doi: 10.21037/cco.2017.06.28Lee S.K. Diff usion tensor and perfusion imaging of brain tumors in high-fi eld MR imaging. // Neuroimaging Clin N Am. – 2012. – V.22. – P.123-34, ix. doi: 10.1016/j.nic.2012.02.001.Lee SK. Diff usion tensor and perfusion imaging of brain tumors in high-fi eld MR imaging. Neuroimaging Clin N Am. 2012;22:123-34, ix. doi: 10.1016/j.nic.2012.02.001.Абсалямова О.В., Кобяков Г.Л., Рыжова М.В., Поддубский А.А., Иноземцева М.В., Лодыгина К.С. Результаты применения современных режимов химиотерапии первой линии в комплексном лечении пациентов с глиобластомой. // Вопросы нейрохирургии им. Н.Н. Бурденко. - 2016. - Т. 80. № 6. - С. 5-14. doi: 10.17116/neiro20168065-14Absalyamova OV, Kobyakov Gl, Ryzhova MV, Poddubskiy AA, Inozemtseva MV, Lodygina KS. Outcomes of application of modern fi rst-line chemotherapy regimens in complex treatment of glioblastoma patients. Zh Vopr Neirokhir Im N N Burdenko. 2019;83(2):17-26. doi: 10.17116/neiro20168065-14Brown T.J., Brennan M.C., Li M., Church E.W., Brandmeir N.J., et al. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. // JAMA Oncol. – 2016. – V.2. – P. 1460-9. doi: 10.1001/jamaoncol.2016.1373Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, et al. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. – 2016. – V.2. – P.1460-9. doi: 10.1001/ jamaoncol.2016.1373Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. // Lancet Oncol. – 2006. – V.7. – P.392–401. doi: 10.1016/S1470-2045(06)70665-9Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401. doi: 10.1016/S1470-2045(06)70665-9Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. // N Engl J Med. – 2005. – V.352. – P.987-996. doi: 10.1056/NEJMoa043330Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987- 996. doi: 10.1056/NEJMoa043330Mesti T., Moltara M.E., Boc M., Rebersek M., Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. // Radiol Oncol. – 2015. – V. 49(1). – P.80–85. doi: 10.2478/raon-2014-0021Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol. 2015;49(1):80–85. doi: 10.2478/raon-2014-0021Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. // Journal of Clinical Oncology. – 2007. – V.25, no. 30. – P.4722-4729. doi: 10.1200/JCO.2007.12.2440Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology.2007;25(30):4722-4729. doi: 10.1200/JCO.2007.12.2440Linhares P., Carvalho B., Figueiredo R., Reis R., Vaz R. Early pseudoprogression following chemoradiotherapy in glioblastoma patients: The Value of RANO Evaluation. // Journal of Oncology. – 2013. – V.2013. – P.1-9. doi: 10.1155/2013/690585Linhares P, Carvalho B, Figueiredo R, Reis R, Vaz R. Early pseudoprogression following chemoradiotherapy in glioblastoma patients: Th e Value of RANO Evaluation. Journal of Oncology. 2013;2013:1-9. doi: 10.1155/2013/690585Puzzilli F., Ruggeri A., Mastronardi L., Di Stefano D., Lunardi P. Long-Term Survival in Cerebral Glioblastoma. Case Report and Critical Review of the Literature. // Tumori Journal. – 1998. - V.84, is.1. – P. 69-74. doi: 10.1177%2F030089169808400115Puzzilli F, Ruggeri A, Mastronardi L, Di Stefano D, Lunardi P. Long-Term Survival in Cerebral Glioblastoma. Case Report and Critical Review of the Literature. Tumori Journal. 1998;84(1):69-74. doi: 10.1177%2F030089169808400115Thomas A.A., Ernstoff M.S., Fadul C.E. Immunotherapy for the treatment of glioblastoma. // Cancer J. - 2012. – V.18(1). – P.59–68. doi: 10.1097/PPO.0b013e3182431a73Th omas AA, Ernstoff MS, Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J. 2012;18(1):59–68. doi: 10.1097/PPO.0b013e3182431a73Zhang W., Fulci G., Wakimoto H., Cheema T.A., Buhrman J.S., et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. // Neoplasia. - 2013. – V.15(6). – P.591–599. doi: 10.1593%2Fneo.13158Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor effi cacy in human glioblastoma models. Neoplasia. 2013;15(6):591–599. doi: 10.1593%2Fneo.13158

The authors declare that there are no conflicts of interest present.